South San Francisco, United States
GenEdit, a biotechnology startup founded in 2016 and headquartered in the United States, is pioneering solutions in the realm of genetic medicines with its innovative slogan: "Delivering the potential of genetic medicines". The company addresses a critical bottleneck in the field—effective delivery systems for genetic treatments.
The backbone of GenEdit is its proprietary NanoGalaxy platform, which comprises a vast library of unique non-viral, non-lipid polymer nanoparticles. This platform allows for the precise screening and identification of polymer nanoparticles, enabling the targeted delivery of genetic medicine payloads to specific tissues, potentially treating a wide array of diseases.
Most recently, GenEdit secured a $24.00M Series A investment on January 23, 2024, with backing from investors including Korea Development Bank, Mirae Asset Venture Investment, and Terra VC, among others. This investment underscores significant confidence in the company's ability to provide therapeutic options where traditional methods may fall short, particularly for diseases with high unmet medical need.
Hopewell Therapeutics, Inc.